KNOWLEDGE WORKER ナレッジワーカー



丸善のおすすめ度

Production of Plasma Proteins for Therapeutic Use H 512 p. 13

Bertolini, J  著

在庫状況 お取り寄せ  お届け予定日 20日間 
価格 特価  \33,760(税込)         
発行年月 2013年02月
出版社/提供元
Wiley-Blackwell
出版国 アメリカ合衆国
言語 英語
媒体 冊子
装丁 hardcover
ページ数/巻数 512 p.
ジャンル 洋書/生命科学・医学/薬学/薬科学
ISBN 9780470924310
商品コード 1011007009
新刊案内掲載月 2012年11月
商品URLhttps://kw.maruzen.co.jp/ims/itemDetail.html?itmCd=1011007009

内容

Sets forth the state of the science and technology in plasmaprotein production With contributions from an international team of eighty leadingexperts and pioneers in the field, Production of Plasma Proteinsfor Therapeutic Use presents a comprehensive overview of thecurrent state of knowledge about the function, use, and productionof blood plasma proteins. In addition to details of the operationalrequirements for the production of plasma derivatives, the bookdescribes the biology, development, research, manufacture, andclinical indications of essentially all plasma proteins withestablished clinical use or therapeutic potential. Production of Plasma Proteins for Therapeutic Use coversthe key aspects of the plasma fractionation industry in fivesections: Section 1: Introduction to Plasma Fractionationinitially describes the history of transfusion and then covers theemergence of plasma collection and fractionation from its earliestdays to the present time, with the commercial and not–for–profitsectors developing into a multi–billion dollar industry. Section 2: Plasma Proteins for Therapeutic Use contains24 chapters dedicated to specific plasma proteins, includingcoagulation factors, albumin, immunoglobulin, and a comprehensiverange of other plasma–derived proteins with therapeuticindications. Each chapter discusses the physiology, biochemistry,mechanism of action, and manufacture of each plasma proteinincluding viral safety issues and clinical uses. Section 3: Pathogen Safety of Plasma Products examinesissues and procedures for enhancing viral safety and reducing therisk of transmissible spongiform encephalopathy transmission. Section 4: The Pharmaceutical Environment Applied to PlasmaFractionation details the requirements and activitiesassociated with plasma collection, quality assurance, compliancewith regulatory requirements, provision of medical affairs support,and the manufacture of plasma products. Section 5: The Market for Plasma Products and the Economicsof Fractionation reviews the commercial environment andeconomics of the plasma fractionation industry including futuretrends, highlighting regions such as Asia, which have the potentialto exert a major influence on the plasma fractionation industry inthe twenty–first century.

目次